The missed EPS estimate by Syra Health suggests potential concerns about profitability, which could negatively impact investor sentiment in the short term. However, the significant beat on sales estimates and year-over-year growth could counterbalance this by indicating strong revenue generation capabilities. The mixed financial results present a complex picture, likely leading to a neutral short-term impact on the stock as investors weigh the implications of missed EPS against strong sales performance.